Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD4 | Q15561 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28072263 | 0.85 | LTA4H (0.55) | MEN1KMT2ALTA4HTSHRNPC1 | |
| SCHEMBL8155454 | 0.85 | LTA4H (0.43) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL919392 | 0.84 | LTA4H (0.59) | HTTSMN1; SMN2ALDH1A1TDP1POLB | |
| SCHEMBL61732 | 0.83 | LTA4H (0.57) | MEN1KMT2ALTA4HTSHRNPC1 | |
| SCHEMBL2751194 | 0.82 | ALDH1A1 (0.47) | TEAD4HTTSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9450784 | 0.81 | LTA4H (0.42) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL919378 | 0.81 | ALDH1A1 (0.53) | HTTALDH1A1TDP1MAPTL3MBTL1 | |
| SCHEMBL922033 | 0.81 | LTA4H (0.41) | SMN1; SMN2FFAR1LTA4HNPC1RAB9A | |
| SCHEMBL157734 | 0.80 | SOS1 (0.40) | HTTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL6154322 | 0.80 | LTA4H (0.59) | SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | claimed |
| CN-103249719-A | Matrix metalloproteinase inhibitors | RANBAXY LAB LTD | 2013-08-14 | — | — | CN | claimed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | claimed |
| CN-101505751-A | 8-hydroxyquinoline compounds and methods thereof | WYETH CORP (US) | 2009-08-12 | — | — | CN | claimed |
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | claimed |
| US-7268164-B2 | Anti-epileptogenic agents | QUEENS UNIVERSITY AT KINGSTON (CA) | 2007-09-11 | — | — | US | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| EP-1572678-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-6930112-B2 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2005-08-16 | — | — | US | claimed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | claimed |
| WO-2004056319-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| US-5783577-A | COMBINATORIAL LIBRARY FOR DRUG SCREENING | TREGA BIOSCIENCES, INC. (US) | 1998-07-21 | — | — | US | claimed |
| WO-1998011438-A1 | SYNTHESIS OF QUINAZOLINONE LIBRARIES AND DERIVATIVES THEREOF | TREGA BIOSCIENCES, INC. (US) | 1998-03-19 | — | — | WO | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| CN-103249719-A | Matrix metalloproteinase inhibitors | RANBAXY LAB LTD | 2013-08-14 | — | — | CN | disclosed |
| EP-0249015-A1 | Silane derivatives, process for their preparation, agents containing them, and their use as pesticides | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-12-16 | — | — | EP | disclosed |
| CN-86107292-A | Novel silane derivatives, process for their preparation, formulations containing them and their use as pesticides | — | 1987-07-29 | — | — | CN | disclosed |
| EP-0224024-A1 | Silane derivatives, process for their preparation, agents containing them and their use as pesticides | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | TEAD4 3240/4885HTT 2828/4885SMN1; SMN2 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.